Insights › Energy & climate › November 14, 2026
Energy & climate · Pipeline & development

Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

PR Newswire (Health) Published: Trial

Updated longer-term analysis, including up to four years of follow-up data in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma treated with OJEMDA®(tovorafenib), will be presented as an oral presentation on November 14 at 3:45 p.m. EST Data expand on clinically...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Energy & climate

See everything in Energy & climate →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.